Glen Burnie, MD – According to filings with the U.S. Securities and Exchange Commission, Diagnostic Biochips is raising $1,502,450.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Greg Alden played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Diagnostic Biochips

Diagnostic Biochips, Inc (DBC) is a Maryland-based biosensor platform technology firm that is redefining measurement in medicine. DBC has developed a proprietary sensor functionalization process and a suite of biosensors that are set to transform the medical monitoring process. Its paradigm-shifting sensors are a cost-effective method for the direct and continuous monitoring of medically important compounds, such as drugs and biomarkers.

To learn more about Diagnostic Biochips, visit http://www.diagnosticbiochips.com/

Contact:
Greg Alden, Chief Executive Officer
410-205-2443
greg.alden@diagnosticbiochips.com
https://www.linkedin.com/in/greg-alden-94b6161/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved